The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 16, 2005

Filed:

Oct. 21, 2002
Applicants:

Michael A. Evans, Palo Alto, CA (US);

Denise Demarais, Los Gatos, CA (US);

Dino DE Cicco, San Jose, CA (US);

Kelvin Ning, Palo Alto, CA (US);

Alexander Khairkhahan, Palo Alto, CA (US);

Tyler Jon Strang, Palo Alto, CA (US);

Jody Maria Cimbalo, Mountain View, CA (US);

Stephen Leeflang, Stanford, CA (US);

Inventors:

Michael A. Evans, Palo Alto, CA (US);

Denise Demarais, Los Gatos, CA (US);

Dino De Cicco, San Jose, CA (US);

Kelvin Ning, Palo Alto, CA (US);

Alexander Khairkhahan, Palo Alto, CA (US);

Tyler Jon Strang, Palo Alto, CA (US);

Jody Maria Cimbalo, Mountain View, CA (US);

Stephen Leeflang, Stanford, CA (US);

Assignee:

Bacchus Vascular, Inc., Santa Clara, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61M031/00 ;
U.S. Cl.
CPC ...
Abstract

Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, agitate the clot and agent, and aspirate broken-up clot from the blood vessel. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.


Find Patent Forward Citations

Loading…